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BACKGROUND: Our objective was to analyse variation in non-metastatic prostate cancer management in the Northern and Yorkshire
region of England.
METHODS:We included 21334 men aged X55, diagnosed between 2000 and 2006. Principal treatment received was categorised into
radical prostatectomy (11%), brachytherapy (2%), external beam radiotherapy (16%), hormone therapy (42%) and no treatment
(29%).
RESULTS: The odds ratio (OR) for receiving a radical prostatectomy was 1.53 in 2006 compared with 2000 (95% CI 1.26–1.86),
whereas the OR for receiving hormone therapy was 0.57 (0.51–0.64). Age was strongly associated with treatment received; radical
treatments were significantly less likely in men aged X75 compared with men aged 55–64 years, whereas the odds of receiving
hormone therapy or no treatment were significantly higher in the older age group. The OR for receiving radical prostatectomy,
brachytherapy or external beam radiotherapy were all significantly lower in the most deprived areas when compared with the most
affluent (0.64 (0.55–0.75), 0.32 (0.22–0.47) and 0.83 (0.74–0.94), respectively) whereas the OR for receiving hormone therapy was
1.56 (1.42–1.71).
CONCLUSIONS:This study highlights the variation and inequalities that exist in the management of non-metastatic prostate cancer in the
Northern and Yorkshire region of England.
British Journal of Cancer (2009) 101, 1839–1845. doi:10.1038/sj.bjc.6605424 www.bjcancer.com
Published online 10 November 2009
& 2009 Cancer Research UK
Keywords: prostate cancer; radical prostatectomy; brachytherapy; radiotherapy; treatment variation
                                                         
Prostate cancer is the most commonly diagnosed cancer in men in
the United Kingdom, accounting for nearly a quarter of all new
male cancer diagnoses (Cancer Research UK, 2009). Prostate
cancer incidence has increased dramatically over the post 20 years
(Majeed et al, 2000; Cancer Research UK, 2009) and much of this is
because of prostate-specific antigen (PSA) testing, which has
resulted in many diagnoses of prostate cancer that would not have
previously been diagnosed (Brewster et al, 2000; Evans and Moller,
2003). Prostate cancer is also the most commonly diagnosed
cancer in men throughout Europe (Ferlay et al, 2007) and the
United States (SEER, 2009).
Treatments for prostate cancer include radical prostatectomy,
radiotherapy (including both brachytherapy and external beam
radiotherapy), hormone therapy, active surveillance and watchful
waiting. Radical treatments, such as surgery and radiotherapy, can
have serious side effects that affect quality of life, such as urinary,
bowel and sexual dysfunction. Side effects for hormone treatment
include osteoporosis, cardiovascular disease, loss of libido and
gynaecomastia. There is no consensus on the best treatment for
early prostate cancer (Selley et al, 1997; NICE, 2002, 2008).
Improving Outcomes Guidance for Urological Cancers published
in 2002 by the National Institute for Clinical Excellence (NICE)
(NICE, 2002) recognised that although observation studies suggest
that radical treatments can improve long-term survival, these
studies are subject to bias in the selection of particular patient
groups. Information on treatment complications and quality of life
after radical treatment must also be taken into consideration when
assessing treatment options. NICE published clinical guidelines for
the diagnosis and treatment of prostate cancer in 2008 (NICE,
2008). Selection of treatment for men with localised prostate
cancer is based on their risk that is derived from a combination of
PSA levels, Gleason score and clinical stage. For example, for men
with low-risk localised prostate cancer, the preferred treatment
option, as recommended by NICE, is active surveillance; however,
other treatment options include prostatectomy, brachytherapy or
conformal radiotherapy. However, in clinical practice, treatment
decisions are more complex and various studies in the United
Kingdom have found that there were wide variations in the
management of prostate cancer (Savage et al, 1997; Donovan et al,
1999; Hanna et al, 2002; Payne and Gillatt, 2007).
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sSocio-demographic factors that are found to be associated with
the treatment received for prostate cancer include ethnicity, socio-
economic status, income and geographical area of residence
(Harlan et al, 2001; Bauvin et al, 2003; Cooperberg et al, 2004;
Krupski et al, 2005). Results show that patients with low-income or
low socio-economic status are less likely to receive surgery or
radiotherapy.
In this paper we describe the variation and management of non-
metastatic prostate cancer using data from a population-based
cancer registry. We explore the trends between 2000 and 2006 and
analyse what factors are associated with treatment received.
MATERIALS AND METHODS
The Northern and Yorkshire Cancer Registry and Information
Service (NYCRIS) is a population-based cancer registry covering a
population of approximately 6.7 million people, collecting data on
all new diagnoses of cancer within its population. Information
collected includes tumour, demographic and treatment informa-
tion. Data for this analysis were extracted from the NYCRIS
database. There were 24946 men diagnosed with prostate cancer
between 2000 and 2006, aged X55 at diagnosis. Men with
metastases, including distant nodal involvement, at diagnosis were
excluded from the analysis (n¼3281). Men who were registered
from a death certificate only and men who had a survival time of
zero days (n¼224) were also excluded from analysis.
The Northern and Yorkshire Cancer Registry and Information
Service NYCRIS records treatment planned at diagnosis, and
therefore, men on active surveillance or watchful waiting will have
no treatment recorded in the cancer registry database although
they may go on to receive treatment in the future. From our data
we identified the principal treatment received using five different
treatment categories: radical prostatectomy, brachytherapy,
external beam radiotherapy, hormone treatment and no treatment.
A further 103 men were excluded from the study as they did not fit
into any of the treatment categories listed; some had chemotherapy
recorded as the treatment received and others had different
surgery codes recorded. We have included a no treatment group as
this consisted of a large percentage of the study population (29%),
although this group includes a mix of patients on active
surveillance, watchful waiting and those who actually receive no
treatment and we cannot distinguish between these three groups
from the data that we have. This resulted in a study population of
21334 men.
Other explanatory variables extracted for each patient were age
at diagnosis, year of diagnosis and postcode of residence at
diagnosis. This postcode was then used to assign patients to a
cancer network of residence and deprivation score. An area-based
measure of deprivation, the Index of Multiple Deprivation 2004
(Noble et al, 2004), was used to measure socio-economic status.
The Income domain of this index was used in which each patient
was assigned a score based on their postcode and these scores were
ranked and split into quintiles: quintile 1 contains patients in the
most affluent areas and quintile 5 contains patients in the most
deprived areas. Patients were also assigned to a Cancer Network
based on their postcode of residence at diagnosis. Cancer networks
bring together health service commissioners and providers, the
voluntary sector and local authorities and are responsible for the
delivery of cancer services within a geographical area. There are
currently three cancer networks covering the NYCRIS region and
these have been used in the analysis presented here: Yorkshire
Cancer Network (YCN), Humber and Yorkshire Coast Cancer
Network (HYC) and North of England Cancer Network (NECN).
Age-standardised rates per 100000 population for all ages were
calculated using the European Standard Population (Office for
National Statistics, 1998). Univariate tests of association between
the explanatory variables and the principal treatment received
were carried out using w
2 test. Multivariate logistic regression was
then used to examine the associations between the explanatory
variables and each mode of treatment received.
RESULTS
Overall, the age-standardised incidence rate, standardised to the
European standard population for all ages, was 93.5 per 100000
population, and this increased from 83.1 per 100000 in 2000 to
96.6 per 100000 in 2004 (Table 1). There were a total of 21334
cases in our study population after exclusions and the number of
these cases diagnosed each year increased from 2572 in 2000 to
3264 in 2006.
Table 2 shows the overall percentage of men receiving each
treatment. Table 3 shows the demographic characteristics of the
study population by treatment group and Figure 1 shows the
principal treatment by year of diagnosis.
Overall, between 2000 and 2006, hormone therapy was the most
common mode of treatment (42%), whereas 29% of patients
received no treatment and 11% of patients received a radical
prostatectomy. The rate of radical prostatectomy increased from
7% in 2000 to 13% in 2006. The brachytherapy rate remained at
approximately 2% over the 7-year period and the external beam
radiotherapy rate increased slightly over time from 14% in 2000 to
18% in 2006. The use of hormone therapy decreased over time
from 48% in 2000 to 32% in 2006. The percentage of patients
receiving no treatment remained between 27 and 29% from 2000 to
2005 but increased to 35% in 2006.
There were higher percentages of men aged 55–64 and 65–74
years who received all three radical treatments when compared
with men aged X75 years; for men aged X75 years, 3% received a
radical prostatectomy, 1% received brachytherapy and 8% received
hormone therapy. Lower percentages of men aged 55–64 years
received hormone therapy (8%) and no treatment (14%) when
compared with men aged X65 years.
There were statistically significant differences in the treatments
received by network of residence. Radical prostatectomies were
more common in YCN (14%) than in HYC (8%) and in NECN
(9%). Brachytherapy was also more common in YCN (3%) than the
other two networks. External beam radiotherapy was more
common in YCN (18%) and in HYC (22%) than in NECN (12%).
Table 1 European age-standardised rates (ASR) per 100000 male
population and 95% confidence intervals (CI) by year for all ages
Year ASR 95% CI
2000 83.1 (80.2–86.0)
2001 92.9 (89.9–96.0)
2002 91.3 (88.3–94.3)
2003 95.7 (92.6–98.8)
2004 97.8 (94.7–100.9)
2005 96.7 (93.7–99.8)
2006 96.6 (93.6–99.7)
All years 93.5 (92.4–94.6)
Table 2 Number and percentage of men receiving each treatment
Treatment n %
Rate per 100000
male population
Radical prostatectomy 2240 10.5 9.9
Brachytherapy 440 2.1 1.9
External beam radiotherapy 3410 16.0 15.1
Hormone therapy 8987 42.1 39.8
No treatment 6257 29.3 27.7
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compared with 43% of patients in HYC and 48% in NECN. Fewer
men in HYC (25%) received no treatment when compared with
YCN (29%) and NECN (31%).
The treatment received also varied by deprivation quintile.
There was a linear trend in the percentage of men who received a
radical prostatectomy: 13% of men in the most affluent areas
received this treatment when compared with only 8% of men in the
most deprived areas. A similar socio-economic gradient was also
observed for brachytherapy and external beam radiotherapy: rates
were highest in the most affluent areas and lowest in the most
deprived areas. Only 35% of men in the most affluent areas
received hormone therapy compared with 48% of men in the most
deprived areas. There was not much difference in the percentage of
men who received no treatment by deprivation quintile. Figure 2
also shows the principal treatment received by deprivation
quintile.
Table 4 shows the results from the multivariate logistic
regression models.
Men diagnosed with prostate cancer in 2006 were 53% more
likely to receive a radical prostatectomy than men diagnosed in
2000 (odds ratio (OR)¼1.53, 95% confidence interval (CI) 1.26–
1.86). There were no statistically significant differences in the
likelihood of receiving brachytherapy or external beam radio-
therapy over time. Men diagnosed in 2006 were 43% less likely to
have hormone treatment than men diagnosed in 2000 (OR¼0.57,
95% CI 0.51–0.64). The odds of having no treatment were 42%
higher in 2006 when compared with 2000 (OR¼1.42, 95% CI
1.27–1.59).
There was a very strong association between age and treatment
received. The odds of having a radical prostatectomy, brachy-
therapy or external beam radiotherapy decreased as age at
diagnosis increased. The OR for men aged X75 years, compared
Table 3 Demographic characteristics of the study population by treatment group
Radical prostatectomy Brachytherapy External beam radiotherapy Hormone therapy No treatment
Characteristic n % n % n % n % n % P-value
a
Diagnosis year
2000 181 7.0 41 1.6 371 14.4 1231 47.9 748 29.1 o0.0001
2001 233 8.0 74 2.5 450 15.5 1356 46.7 792 27.3
2002 280 9.4 51 1.7 400 13.4 1441 48.3 813 27.2
2003 331 10.7 52 1.7 459 14.8 1393 45.0 859 27.8
2004 409 12.5 87 2.7 538 16.5 1286 39.4 940 28.8
2005 396 12.2 75 2.3 594 18.3 1233 37.9 956 29.4
2006 410 12.6 60 1.8 598 18.3 1047 32.1 1149 35.2
Age group
55–64 years 1305 58.3 242 55.0 1180 34.6 740 8.2 887 14.2 o0.0001
65–74 years 870 38.8 193 43.9 1972 57.8 3097 34.5 2453 39.2
75+ year 65 2.9 5 1.1 258 7.6 5150 57.3 2917 46.6
Network
YCN 1128 13.5 277 3.3 1530 18.4 2953 35.5 2440 29.3 o0.0001
HYC 277 7.8 59 1.7 783 22.1 1532 43.2 895 25.2
NECN 835 8.8 104 1.1 1097 11.6 4502 47.6 2922 30.9
Deprivation quintile
1 (most affluent) 576 13.2 137 3.1 794 18.1 1525 34.9 1343 30.7 o0.0001
2 550 11.7 126 2.7 852 18.1 1832 39.0 1342 28.5
3 468 11.4 93 2.3 635 15.4 1714 41.7 1201 29.2
4 327 8.4 51 1.3 546 14.0 1866 47.8 1117 28.6
5 (most deprived) 319 7.5 33 0.8 583 13.8 2050 48.4 1254 29.6
Abbreviations: HYC¼Humber and Yorkshire Coast Cancer Network; NECN¼North of England Cancer Network; YCN¼Yorkshire Cancer Network.
aChi-squared P-value.
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were 0.02 (95% CI 0.01–0.02), for receiving a brachytherapy were
0.01 (95% CI 0.004–0.03) and for receiving an external beam
radiotherapy were 0.08 (95% CI 0.07–0.10). The odds of receiving
hormone therapy, and no treatment significantly increased as age
at diagnosis increased. The OR for men aged X75 years, compared
with men aged 55–64 years, for receiving hormone therapy were
7.67 (95% CI 7.00–8.41) and for receiving no treatment were 2.15
(95% CI 1.98–2.35).
For all treatment modalities there were statistically significant
differences across the networks. Compared with YCN, radical
prostatectomy and brachytherapy were less likely in HYC
(OR¼0.54, 95% CI 0.47–0.63 and OR¼0.54, 95% CI 0.40–0.71)
and in NECN (OR¼0.64, 95% CI 0.58–0.71 and OR¼0.36, 95% CI
0.28–0.45). External beam radiotherapy was more likely in HYC
(OR¼1.35, 95% CI 1.22–1.50) and less likely in NECN (OR¼0.58,
95% CI 0.53–0.63) compared with YCN. The odds of receiving
hormone therapy were more likely in both HYC and NECN
compared with YCN (OR¼1.36, 95% CI 1.25–1.49 and OR¼1.64,
95% CI 1.53–1.75). The odd of receiving no treatment were
significantly lower in HYC than in YCN (OR¼0.81, 95% CI 0.74–
0.88) and significantly higher in NECN than in YCN (OR¼1.09,
95% CI 1.02–1.17).
The odds of receiving a radical prostatectomy, brachytherapy or
external beam radiotherapy were all significantly lower in the most
deprived areas compared with the most affluent (OR¼0.64, 95%
CI 0.55–0.75; OR¼0.32, 95% CI 0.22–0.47; and OR¼0.83, 95% CI
0.74–0.94, respectively). The odds of receiving hormone therapy
increased as deprivation increased (OR¼1.56, 95%CI 1.42–1.71)
for most deprived areas compared with most affluent areas. The
association between deprivation and receiving no treatment was of
borderline statistical significance (P¼0.05); the magnitude of the
effect was similar in all deprivation quintiles relative to the most
affluent quintile but only statistically significantly different in
quintiles 2 and 4 (OR¼0.90, 95% CI 0.82–0.99 and OR¼0.86,
95% CI 0.78–0.95 respectively).
DISCUSSION
Our results show that there are variations in the modality of
treatment received in men with non-metastatic prostate cancer in
the Northern and Yorkshire region. Younger men were more likely
to receive radical treatments, radical prostatectomy, brachytherapy
and external beam radiotherapy, as were men from the more
affluent areas, whereas older men and men from the more deprived
areas were more likely to receive hormone therapy. There were
also differences by cancer network of residence. Over the study
period, the rates of radical prostatectomies increased whereas the
rate of hormone therapy decreased.
Socio-demographic factors, such as age, ethnicity, geographic
region of residence and income, have all been found to be
associated with prostate cancer treatment elsewhere, including
studies from the United States and France (Harlan et al, 2001;
Bauvin et al, 2003; Cooperberg et al, 2004; Krupski et al, 2005). We
also found significant associations between treatment and age,
deprivation and geographic region of residence. Radical treatments
were less likely in the older population and men from deprived
areas and may be explained by differences in life expectancy, with
both these groups having shorter life expectancy (Bajekal, 2005).
Strengths and limitations of the study
One of the main strength of this study is that it is population based
and includes data from over 21000 cases, and therefore produced
statistically robust estimates. It is also recognised that the coding
Table 4 Association between treatment received and demographic variables, odds ratios (OR) and 95% confidence intervals (CI). Results from
multivariate logistic regression
Radical
prostatectomy Brachytherapy
External beam
radiotherapy
Hormone
therapy
No
treatment
All radical
treatment
Characteristic OR 95%CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Diagnosis year
2000 1.00 — 1.00 — 1.00 — 1.00 — 1.00 — 1.00 —
2001 1.05 (0.85–1.30) 1.48 (1.00–2.18) 1.03 (0.88–1.21) 1.01 (0.90–1.13) 0.93 (0.83–1.05) 1.10 (0.96–1.27)
2002 1.35 (1.09–1.66) 1.00 (0.66–1.53) 0.86 (0.73–1.01) 1.06 (0.95–1.19) 0.93 (0.82–1.04) 1.02 (0.89–1.18)
2003 1.47 (1.20–1.79) 0.91 (0.60–1.39) 0.96 (0.82–1.12) 0.94 (0.84–1.05) 0.96 (0.86–1.08) 1.16 (1.01–1.33)
2004 1.67 (1.36–2.02) 1.32 (0.90–1.93) 1.01 (0.87–1.18) 0.77 (0.69–0.87) 1.03 (0.92–1.16 1.37 (1.19–1.57)
2005 1.55 (1.27–1.89) 1.15 (0.78–1.70) 1.15 (0.99–1.33) 0.73 (0.66–0.82) 1.07 (0.95–1.20) 1.43 (1.24–1.63)
2006 1.53 (1.26–1.86) 0.84 (0.56–1.26) 1.09 (0.94–1.26) 0.57 (0.51–0.64) 1.42 (1.27–1.59) 1.30 (1.14–149)
Age group
55–64 years 1.00 — 1.00 — 1.00 — 1.00 — 1.00 — 1.00 —
65–74 years 0.27 (0.24–0.29) 0.40 (0.33–0.49) 0.80 (0.74–0.87) 2.72 (2.48–2.98) 1.59 (1.46–1.74) 0.32 (0.29–034)
75+ years 0.02 (0.01–0.02) 0.01 (0.004–0.03) 0.08 (0.07–0.10) 7.67 (7.00–8.41) 2.15 (1.98–2.35) 0.02 (0.02–0.03)
Network
YCN 1.00 — 1.00 — 1.00 — 1.00 — 1.00 — 1.00 —
HYC 0.54 (0.47–0.63) 0.54 (0.40–0.71) 1.35 (1.22–1.50) 1.36 (1.25–1.49) 0.81 (0.74–0.88) 0.87 (0.79–0.97)
NECN 0.64 (0.58–0.71) 0.36 (0.28–0.45) 0.58 (0.53–0.63) 1.64 (1.53–1.75) 1.09 (1.02–1.17) 0.45 (0.41–0.48)
Deprivation quintile
1 (most affluent) 1.00 — 1.00 — 1.00 — 1.00 — 1.00 — 1.00 —
2 0.94 (0.82–1.08) 0.92 (0.71–1.18) 1.00 (0.89–1.12) 1.17 (1.06–1.28) 0.90 (0.82–0.99) 0.95 (0.86–1.05)
3 0.96 (0.84–1.10) 0.80 (0.61–1.05) 0.84 (0.74–0.95) 1.28 (1.17–1.41) 0.92 (0.84–1.01) 0.81 (0.73–0.91)
4 0.75 (0.64–0.87) 0.55 (0.39–0.76) 0.86 (0.76–0.97) 1.50 (1.37–1.65) 0.86 (0.78–0.95) 0.70 (0.62–0.78)
5 (most deprived) 0.64 (0.55–0.75) 0.32 (0.22–0.47) 0.83 (0.74–0.94) 1.56 (1.42–1.71) 0.91 (0.83– 1.00) 0.60 (0.54–0.68)
Abbreviations: HYC¼Humber and Yorkshire Coast Cancer Network; NECN¼North of England Cancer Network; YCN¼Yorkshire Cancer Network.
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sof treatment procedures were of high quality and well recorded
with the Northern and Yorkshire Cancer Registry and Information
Service (United Kingdom Association of Cancer Registries, 2009).
One of the main limitations of this study is that we do not have
data available on stage and grade of the tumours, or PSA levels, as
these data items are not routinely collected by NYCRIS. The
recently established National Cancer Intelligence Network aims to
develop a national cancer data repository, involving linking the
cancer registration data with other data sources. Work to link
urological data from cancer registries to Hospital Episode Statistics
and data from the clinical database of the British Association of
Urological Surgeons (BAUS) is underway (Ayres et al, 2008) and
data sets such as these will provide valuable information on stage
and grade so that full case-mix adjustment can be made.
The recent increase in PSA testing, which has been found to be
more common in affluent areas (Melia et al, 2004; Rowan et al,
2008), has resulted in many more cancers being diagnosed earlier
and these cancers may be more likely to receive radical treatments.
Schro ¨der et al (2009) found that PSA-based screening reduced the
rate of death from prostate cancer by 20% but was associated with
a high risk of diagnosing many men who would not have clinical
symptoms during their lifetime.
The other main limitation of this study is regarding the use and
interpretation of the no treatment group. This group contains all
patients who had no record of receiving any treatment. The routine
collection of data within the cancer registry includes treatment
intent at diagnosis. The no treatment group in our study will
include men on active surveillance and watchful waiting and some
of this group may go on to receive some form of treatment;
however, this will not be recorded on the cancer registry database.
This group will also include patients who actually received no
treatment and there may also be some other cases in which we do
not know whether the patient received any treatment. Therefore,
results concerning this group should be interpreted with caution.
We have excluded all records only notified from Death Certificates
or with zero survival (0.9% of study population), thus reducing
bias from this source.
The percentage of men who received no treatment in 2006
increased to 35% compared with 27–29% between 2000 and 2005.
This increase was observed across all cancer networks as more
men may be opting for deferred treatment. This increase may just
be because of chance and further monitoring of trends is required
and when national data become available, trends across other areas
can also be analysed.
There are important differences between active surveillance and
watchful waiting, although patients on both treatment options are
spared the side effects of unnecessary treatment. Active surveil-
lance is an option for men who are suitable for radical treatment
but for whatever reasons choose to delay treatment; however, if
there are signs of tumour progression, then radical treatment may
be offered. Watchful waiting is an option for men not suitable for
radical treatments, such as older men or those with poor general
health, or some men presenting with asymptomatic advanced
disease; if the cancer progresses then these men will generally
receive hormone therapy. Our study does not allow us to
distinguish between these two groups. However, there was some
evidence that men from more deprived areas were less likely to
receive no treatment but with borderline significance. Treatment
decisions, including the option of active surveillance or watchful
waiting, should be made taking into consideration the needs and
preferences of the patients and after careful consideration of the
options and discussions with their healthcare professionals (NICE,
2008). These decisions could be related to educational levels and
the deliberation to choose to delay treatment may be easier and
more likely in men from better educated groups. Kane et al (2003)
found that the education levels of the patients were predictive of
primary treatment for prostate cancer but the effect of education
depends on age.
Treatment options
The use of radical prostatectomy increased nearly 20-fold between
1991 and 1999 in England (Oliver et al, 2003), and in our study
population the odds of having a radical prostatectomy increased
significantly by 53% from 2000 to 2006. The rise in surgery may be
because of an increase in the numbers of surgeons with the
technical ability and enthusiasm to perform this procedure.
Surgery is an option for men whose tumours are confined to the
prostate and who are expected to live for at least 10 years (NICE,
2002). It can cause significant complications that affect quality of
life, such as impotence and incontinence; generally, it will be the
fittest men with localised prostate cancer who are selected for
surgery. We found a very strong association between age and
surgery. We also found that men from the most deprived areas
were 36% less likely to have a radical prostatectomy than men
from the most affluent areas. Co-morbidity could explain part of
this relationship as we would expect greater levels of co-
morbidities in men in the more deprived areas and therefore
these men will be less likely to be suitable for surgery. However, a
study in the Netherlands found that for prostate cancer patients
there was no association between socio-economic status and levels
of co-morbidity (Schrijvers et al, 1997). A study in Western
Australia found that men who received radical prostatectomy had
less co-morbidities and were more socio-economically advantaged
(Hall et al, 2005). Although radiotherapy is non-invasive, it shares
most of the complications and side effects that follow surgery.
Therefore, the extent that co-morbidities may have in explaining
the inequalities that we observed in external beam radiotherapy, in
which men from more deprived areas were less likely to receive
external beam radiotherapy, is not clear.
Brachytherapy is an option suitable for men with smaller
prostates who may choose any other radical treatment, including
patients who are not suitable for surgery (Ash et al, 1998). The use
of brachytherapy in general has become more common throughout
Europe (Guedea et al, 2007). This was the least common mode of
treatment received in our study population. We did, however, find
a large deprivation gap in the odds of getting brachytherapy; men
from the most deprived areas were 68% less likely to receive this
form of treatment than men from the most affluent areas after
adjustment for age and network, suggesting a lack of access to this
treatment for men from socially deprived areas. The odds of
receiving brachytherapy were also reduced in older men when
compared with younger men. Brachytherapy can be technically
challenging in larger prostate glands, although some centres may
downsize the gland with hormones before brachytherapy. The
prostate gland increases in size with age and hence this form of
treatment may not be suitable for older men.
Hormone therapy is the recommended treatment for men with
locally advanced prostate cancer either with or without external
beam radiotherapy (NICE, 2002). A recent study by Widmark et al
(2009) found that the addition of local radiotherapy to endocrine
treatment halved the 10-year prostate cancer-specific mortality.
Hormone therapy was the most common form of treatment
received in our study population and was more common among
older men and men from more deprived areas. This may suggest
that men from deprived areas present with more advanced cancers
and that radical treatment might not be suitable for these patients.
Without information on stage, we are unable to confirm this.
However, over time we did see that the hormone treatment rate
decreased from 48% to 32%, and over this same time period the
rate of surgery increased.
Woods et al (2006) reviewed the origins of socio-economic
inequalities in cancer survival and found many studies that showed
differential treatment between socio-economic groups. We also
found that men from more deprived areas were less likely to
receive radical treatments and more likely to receive hormone
treatment. For prostate cancer there is a lower likelihood of
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from more deprived areas are less likely to be offered radical
treatments.
Other studies
Radical treatment for prostate cancer can cause serious side effects
that will affect quality of life, such as urinary, bowel and sexual
dysfunction; therefore, it is important to assess which treatment is
optimal for men with prostate cancer. A few studies have
compared survival from different treatment groups in terms of
prostate cancer-specific survival and overall survival. A Scandina-
vian trial, which compared radical prostatectomy and watchful
waiting, found that radical prostatectomy reduces disease-specific
mortality and overall mortality after 10 years (Bill-Axelson et al,
2005). A study, which compared prostatectomy, brachytherapy
and no definitive treatment, found that men treated with either the
prostatectomy or brachytherapy had better survival (Tward et al,
2006). Other case series studies have shown that biochemical
failure rates are similar for radical prostatectomy, brachytherapy
and external beam radiotherapy (Kupelian et al, 2004; Potters et al,
2004). The Prostate Cancer Outcomes Study found that after 5
years men treated by radical prostatectomy experienced worse
urinary incontinence than men treated with external beam
radiotherapy; however, both groups had similar overall sexual
dysfunction (Potosky et al, 2004). Other studies have assessed
health-related quality of life, such as sexual functioning, urinary
incontinence and bowel functioning, and found that this varies by
treatment (Buron et al, 2007; Litwin et al, 2007; Ferrer et al, 2008;
Sanda et al, 2008).
Network differences in treatment received
We found that there were differences between the Cancer Networks
in the treatment men received. This will be partly because of the
local availability of the treatment options – brachytherapy was
only available in Leeds and Newcastle during our study period. The
absence of any clarity about the right treatment for some men
inevitably leads to variation in practice.
Another factor that may influence treatment decisions and effect
on the geographic inequalities that we observed are the waiting
times for treatments such as radiotherapy and surgery. Some of the
differences between networks in the treatment rates that we
observed may be because of differences in waiting times. The NHS
Cancer Plan published in 2000 (Department of Health, 2000) set
out standards for cancer waiting times, including a 31-day
standard from diagnosis/decision to treat to first treatment. The
Cancer Reform Strategy (Department of Health, 2007) extended
this standard to cover all cancer treatments. The largest effect that
this will have is on radiotherapy delivery, in which increased
capacity will be needed in some areas, and the implementation
date for the application of this target to patients who receive
radiotherapy will be consequently delayed. If all cancer networks
are able to meet this standard, then the patient’s choice of
treatment should be less influenced by treatment delays.
In the United Kingdom, the Prostate Testing for Cancer and
Treatment (ProtecT) trial has been set up to evaluate treatments
for localised prostate cancer (http://www.epi.bris.ac.uk/protect/).
This study invites asymptomatic men aged 50–69 to test for
prostate cancer using PSA testing. Those who have raised age-
related PSA levels are offered a transrectal ultrasound-guided
biopsy and, when they are found to have localised prostate cancer,
they are asked to consent to a three-armed treatment trial of
prostatectomy, radiotherapy or active monitoring. Those who did
not consent to randomisation could select one of the treatments.
Recruitment began in 2001 and continued until 2008, with follow-
up planned for 10–15 years. Studies such as this will provide vital
information about which treatment is best for men with localised
prostate cancer. Over the study period in our analysis, Newcastle
was the major recruiting centre for this study with Leeds joining
around 2005, and hence some of the men in our study would have
been involved in this study. Results so far show that patients who
self-selected active monitoring were more affluent than those
randomised to that treatment (Mills et al, 2006). Levels of PSA
testing are more common in more affluent areas of England and
Wales (Melia et al, 2004; Rowan et al, 2008), and there are
associations between affluence, PSA testing and treatment choices.
One of the key goals of the recent Department of Health Cancer
Reform Strategy is to reduce inequalities in cancer incidence,
access to services and outcomes (Department of Health, 2007).
Inequalities in prostate cancer incidence have been reported for
England with higher incidence rates observed in the most affluent
areas (National Cancer Intelligence Network, 2008). Much of the
recent increase in prostate cancer incidence is because of the
increased use of PSA testing, resulting in the diagnosis of many
asymptomatic cancers that would never previously have been
diagnosed in life. There are wide variations in rates of PSA testing
by GP practice (Gavin et al, 2004) and there is evidence that PSA
testing is more common in more affluent areas in England and
Wales (Melia et al, 2004; Rowan et al, 2008). There are also
inequalities in prostate cancer survival and the deprivation gap in
survival has increased between the late 1980s and late 1990s
(Rowan et al, 2008), although much of this will be influenced by
variations in PSA testing. We have also found socio-economic
inequalities in the treatment received for men diagnosed with
prostate cancer.
CONCLUSIONS
This study highlights the wide variation that exists in the
management of non-metastatic prostate cancer in the Northern
and Yorkshire region of England. We have used population-based
cancer registry data and found that the principal method of
treatment received was found to vary by age at diagnosis, cancer
network of residence and deprivation quintile.
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